


Remarks

To respond to the Examiner's objection, the pending claims 8 to 15 have been canceled and new claims 16 to 22 have been added to reflect that the statutory class of the claims is neither compound nor composition, but rather method. The compounds described in the application are basically known in the art for other uses, but not for the unexpected and unobvious ophthalmological use disclosed and taught by the present invention. In the drafting of the new claims 16 to 22, the structural formula in claim 16 has been drawn in a more appropriate manner. In addition, there was a typographical error in claims 1 and 15 in that the upper limit of R_F was stated to be $F_{12}C_{23}$, whereas it should properly be $F_{12}C_{25}$. This typographical error has been corrected in new claim 16.

In light of the foregoing remarks, this application should be in condition for allowance, and early passage of this case to issue is respectfully requested. If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

It is respectfully requested that, if necessary to effect a timely response, this paper be considered as a Petition for an Extension of Time, time sufficient, to effect a timely response, and shortages in this or other fees, be charged, or any overpayment in fees be credited, to the Deposit Account of the undersigned, Account No. 500601 (Docket no. 754-X01-002).

Respectfully submitted,



Martin Fleit, Reg. #16,900

Martin Fleit
FLEIT KAIN GIBBONS GUTMAN & BONGINI
601 Brickell Key Drive #404
Miami, Florida 33131
Tel: 305-416-4490; Fax: 305-416-4489
e-mail: MFleit@FocusOnIP.com